🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pieter Sonneveld

Europeana Foundation

ORCID: 0000-0002-0808-2237

Also affiliated with Erasmus MC Cancer Institute, Erasmus University Rotterdam

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma”.

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

UNC Libraries(2020)10.17615/tmgg-w910

N/A

0DataRank · unranked

0 citations

Suzanne Lentzsch, Pieter Sonneveld, Sonja Zweegman, Hong Xie, Xiang Qin +13 more

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

The Lancet Haematology(2022)10.1016/s2352-3026(22)00045-x

N/A

0DataRank · unranked

24 citations

Lori M Minasian, Vishal Bhatnagar, Franco Cavalli, R Angelo De Claro, Amylou C Dueck +35 more

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

Journal of Clinical Oncology(2025)10.1200/jco-24-01893

N/A

0DataRank · unranked

142 citations

Faith E. Davies, Mehmet Samur, Jill Corre, Mattia D’Agostino, Martin Kaiser +41 more